Protagenic Therapeutics, Inc.
PTIX
$0.92
-$0.11-10.32%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 80.95% | 377.10% | 360.00% | -49.30% | -1,459.03% |
| Total Depreciation and Amortization | -34.13% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | 635.61% | -100.00% | -100.00% | -- |
| Total Other Non-Cash Items | -96.91% | -900.00% | -- | -- | -- |
| Change in Net Operating Assets | -115.46% | 1,273.84% | -10.58% | -1,783.21% | 475.48% |
| Cash from Operations | 46.07% | 131.18% | -44.15% | -339.63% | -610.67% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -124.47% | 100.00% | 100.00% | -- |
| Total Debt Issued | -- | 100.00% | -100.00% | -101.85% | -45.88% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 2,172,500.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -35.47% | -100.00% | 88.14% | 420.13% |
| Foreign Exchange rate Adjustments | 100.94% | -22.04% | -100.05% | 127.48% | -2,690.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -123.11% | -982.31% | -6,317.07% | -113.91% | 473.27% |